AZ turns the corner

AstraZeneca Plc delivered a 4% increase in product sales in the fourth quarter of 2017, pointing towards a return to growth. This comes nearly four years after it fought off a hostile takeover bid, and started to rebuild its portfolio to offset the expiry of patents on its core products.

Full text available to subscribers only. Click here for information on subscribing to MedNous.


United Kingdom